VANCOUVER, BC/ ACCESS Newswire/ April 23, 2025/ BioNxt Solutions Inc., a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its ...

In the present study, in part 1 (fasting condition trial), the 90% CIs of both the mean AUC 0-12 and C max ratios lay within the acceptance range of 0.80, 1.25. Therefore, under fasting conditions ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended ...

(RTTNews) - Eton Pharmaceuticals (ETON) announced positive results from bioequivalence study of ET-600, a patented oral solution of desmopressin under development for the treatment of central ...

Xspray Pharma has now completed the population pharmacokinetic (PopPK) modeling that constitutes key regulatory documentation ...